Professor Umber Cheema's research interests focus on 3D bio-engineering. She is the Head of the UCL Centre for 3D Models of Health and Disease and Vice Dean for Innovation and Enterprise for the Faculty of Medical Sciences. Her work focuses on developing biomimetic tissue models, with a specific aim for these to be used to test novel therapeutic interventions. Umber was part of the team to developed a patent-protected plastic compression technique for collagen I hydrogels used to develop biomimetic tissue models. Following on from this, she was awarded a BBSRC David Phillips fellowship to start her independent career in 2008. Her work currently focuses on engineering 3D tumours, which are in vitro models of solid tumour growth. Here, the spatial micro-architecture of a tumour and its surrounding stroma has been reproduced in vitro, with evidence of tumour invasion into surrounding 'normal' tissue and interaction of the cancer with engineered vascular networks. These engineered models have also been used to control biophysical cues that direct the potency of stem cells. The development of humanised in vitro models is a key aspect of her research, as well as the incorporation of patient-derived cells.
Professor Umber Cheema's research interests focus on 3D bio-engineering. She is the Head of the UCL Centre for 3D Models of Health and Disease and Vice Dean for Innovation and Enterprise for the Faculty of Medical Sciences. Her work focuses on developing biomimetic tissue models, with a specific aim for these to be used to test novel therapeutic interventions. Umber was part of the team to developed a patent-protected plastic compression technique for collagen I hydrogels used to develop biomimetic tissue models. Following on from this, she was awarded a BBSRC David Phillips fellowship to start her independent career in 2008. Her work currently focuses on engineering 3D tumours, which are in vitro models of solid tumour growth. Here, the spatial micro-architecture of a tumour and its surrounding stroma has been reproduced in vitro, with evidence of tumour invasion into surrounding 'normal' tissue and interaction of the cancer with engineered vascular networks. These engineered models have also been used to control biophysical cues that direct the potency of stem cells. The development of humanised in vitro models is a key aspect of her research, as well as the incorporation of patient-derived cells.